Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”

---

In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below.

Figure 3 

Utilisation of insulin glargine 300 IU/ml (Gla-300) as a % of total insulin glargine (DDD based) across Europe over time.

Figure 4 

Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.